Business
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability of technical successin Phase 3 full approval trial FDA granted Fast Track designation for dual mechanism therapy as a treatment for non-small cell lung cancer (NSCLC) CHICAGO, April 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-sta
About this update from Maia Biotechnology, Inc.
[{"type":"image","alt":"MAIA Biotechnology, Inc.","displaySize":"","headline":null,"caption":"MAIA Biotechnology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/fbd77a311f7c68878bc3292efbebb483"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jAgl2ElYsXtsex6FmAJkng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/fbd77a311f7c68878bc3292efbebb483","width":300,"height":114}},"lazy":false},{"type":"text","content":"Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential","length":152,"tagName":"p"},{"type":"text","content":"Statistical assessments point to high probability of technical successin Phase 3 full approval trial ","length":101,"tagName":"p"},{"type":"text","content":"FDA granted Fast Track designation for dual mechanism therapy as a treatment for non-small cell lung cancer (NSCLC)","length":115,"tagName":"p"},{"type":"text","content":"CHICAGO, April 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that net proceeds from its $33 million public offering of common stock in March 2026 are expected to fully fund the Company’s ongoing pivotal Phase 3 clinical trial of its lead investigational therapy, ateganosine, as a treatment for non-small cell lung cancer (NSCLC). Ateganosine is a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the drug in third line (3L) NSCLC treatment.","length":776,"tagName":"p"},{"type":"text","content":"“We are grateful for the support and confidence shown by the healthcare-dedicated investors and existing shareholders who participated in our recent offering. The $33 million raise is expected to complete the necessary funding for our pivotal Phase 3 trial through completion,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA","length":344,"tagName":"p"},{"type":"text","content":"“Statistical assessments point to a high probability of technical succ...